Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
- PMID: 33614478
- PMCID: PMC7886973
- DOI: 10.3389/fonc.2020.584367
Enhancing the Efficacy of Tumor Vaccines Based on Immune Evasion Mechanisms
Abstract
Tumor vaccines aim to expand tumor-specific T cells and reactivate existing tumor-specific T cells that are in a dormant or unresponsive state. As such, there is growing interest in improving the durable anti-tumor activity of tumor vaccines. Failure of vaccine-activated T cells to protect against tumors is thought to be the result of the immune escape mechanisms of tumor cells and the intricate immunosuppressive tumor microenvironment. In this review, we discuss how tumor cells and the tumor microenvironment influence the effects of tumor infiltrating lymphocytes and summarize how to improve the efficacy of tumor vaccines by improving the design of current tumor vaccines and combining tumor vaccines with other therapies, such as metabolic therapy, immune checkpoint blockade immunotherapy and epigenetic therapy.
Keywords: combination therapies; immune evasion; immunotherapy; tumor microenvironment; tumor vaccines.
Copyright © 2021 Chen, Zhang, Zhou, Hu, Li, He and Li.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Vaccines for established cancer: overcoming the challenges posed by immune evasion.Nat Rev Cancer. 2016 Apr;16(4):219-33. doi: 10.1038/nrc.2016.16. Epub 2016 Mar 11. Nat Rev Cancer. 2016. PMID: 26965076 Review.
-
Research progress of nanovaccine in anti-tumor immunotherapy.Front Oncol. 2023 Aug 24;13:1211262. doi: 10.3389/fonc.2023.1211262. eCollection 2023. Front Oncol. 2023. PMID: 37692854 Free PMC article. Review.
-
Epigenetics and immunotherapy: The current state of play.Mol Immunol. 2017 Jul;87:227-239. doi: 10.1016/j.molimm.2017.04.012. Epub 2017 May 14. Mol Immunol. 2017. PMID: 28511092 Review.
-
Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10. Cancer Immunol Immunother. 2016. PMID: 26961085 Free PMC article.
-
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.Front Immunol. 2018 Mar 22;9:610. doi: 10.3389/fimmu.2018.00610. eCollection 2018. Front Immunol. 2018. PMID: 29623082 Free PMC article. Review.
Cited by
-
Enhancing the Efficiency of Mild-Temperature Photothermal Therapy for Cancer Assisting with Various Strategies.Pharmaceutics. 2022 Oct 24;14(11):2279. doi: 10.3390/pharmaceutics14112279. Pharmaceutics. 2022. PMID: 36365098 Free PMC article. Review.
-
The Importance of Metabolism for Immune Homeostasis in Allergic Diseases.Front Immunol. 2021 Jul 28;12:692004. doi: 10.3389/fimmu.2021.692004. eCollection 2021. Front Immunol. 2021. PMID: 34394086 Free PMC article. Review.
-
Identification and Validation of the lncRNA BACE1-AS as Immune-Related Influencing Factor in Tumorigenesis following Pan-Carcinoma Analysis.J Immunol Res. 2021 Dec 8;2021:1589864. doi: 10.1155/2021/1589864. eCollection 2021. J Immunol Res. 2021. PMID: 34926701 Free PMC article.
-
Analysis of thymic generation of shared T-cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild-type antigens.Cancer Med. 2023 Jun;12(12):13486-13496. doi: 10.1002/cam4.6002. Epub 2023 Apr 28. Cancer Med. 2023. PMID: 37114587 Free PMC article.
-
Trichostatin A-modified vaccine provides superior protection against ovarian cancer formation and development.Braz J Med Biol Res. 2024 May 17;57:e12874. doi: 10.1590/1414-431X2024e12874. eCollection 2024. Braz J Med Biol Res. 2024. PMID: 38775545 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials